A new study suggests that levetiracetam could be considered as an alternative therapy to phenytoin for the second-line management of pediatric convulsive status epilepticus.
Two news randomized studies have answered a longstanding clinical question: Is levetiracetam (Keppra) superior to phenytoin (Dilantin) for second-line treatment of convulsive status epilepticus (CSE)? The results indicate that either drug can stop prolonged seizures in at least 50 percent of children reports Neurology Today.
These studies were the first randomized clinical trials to compare the efficacy and safety of two anti-convulsant medications in the second-line management of CSE, both published in the April 17 online edition of TheLancet.
Lead Investigator Comments
Richard Appleton, MD, professor of pediatric neurology at Alder Hey Children’s Health Park in Liverpool, England told Neurology Today “This provides new and unique scientifically-robust data to better inform pediatricians on how to improve their management of CSE in children. Specifically, it shows that both levetiracetam and phenytoin could be used as a first-choice anticonvulsant in the second-stage of pediatric CSE.
Richard Appleton, MD, professor of pediatric neurology at Alder Hey Children’s Health Park in Liverpool, EnglandSource: Journals